Ferring divests testosterone drug in new deal
In move towards simplifying its urology treatment portfolio, Ferring has divested two drugs, one of which is a topical treatment for adult male hypogonadism.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Swiss pharmaceutical firm Ferring has divested two urology-related medicines.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Millions of vaccines waiting in warehouses
For subscribers
